Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839162 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2EPHX2EPHX1LMNAHTT | |
| SCHEMBL8812116 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2EPHX2EPHX1LMNAHTT | |
| Hydrochloric Acid SCHEMBL5988473 | 0.98 | SMN1; SMN2 (0.51) | SMN1; SMN2EPHX2EPHX1LMNAHTT | |
| Hydrochloric Acid SCHEMBL5988469 | 0.98 | SMN1; SMN2 (0.51) | SMN1; SMN2EPHX2EPHX1LMNAHTT | |
| Valine SCHEMBL10724646 | 0.88 | SLC7A5 (0.47) | SMN1; SMN2EPHX2EPHX1LMNAHTT | |
| SCHEMBL11154682 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2EPHX2EPHX1LMNAHTT | |
| Hydrochloric Acid SCHEMBL11151714 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2EPHX2EPHX1LMNAHTT | |
| SCHEMBL105165 | 0.73 | GRIN2D (0.52) | SMN1; SMN2EPHX2EPHX1LMNAHTT | |
| SCHEMBL1758676 | 0.73 | SMN1; SMN2 (0.58) | SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL5079704 | 0.69 | GRIN2D (0.43) | SMN1; SMN2EPHX2EPHX1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008077194-A1 | RECEPTOR AGONISTS | XENOME LTD (AU) | 2008-07-03 | — | — | WO | claimed |
| US-6890902-B2 | Cytotoxic modified lactoferrin peptides | ALPHARMA AS (NO) | 2005-05-10 | — | — | US | claimed |
| US-6586402-B1 | LH-RH peptide analogues, their uses and pharmaceutical compositions containing them | LABORATOIRE THERAMEX (MC) | 2003-07-01 | — | — | US | claimed |
| US-20030022821-A1 | Bioactive peptides | ALPHARMA AS | 2003-01-30 | — | — | US | claimed |
| EP-1109827-A2 | BIOACTIVE PEPTIDES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | claimed |
| WO-2000012542-A2 | CYTOTOXIC LACTOFERRIN DERIVATIVES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | claimed |
| US-5679640-A | BINDING TO MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) E.G. HLA-DR'S, TO INHIBIT HLA-DR RESTRICTED T CELL ACTIVATION; AUTOIMMUNE DISEASES; ANTIARTHRITIC AGENTS | CYTEL CORPORATION (US) | 1997-10-21 | — | — | US | claimed |
| EP-0652893-A1 | KININOGENASE INHIBITORS | SZELKE, Michael (GB) | 1995-05-17 | — | — | EP | claimed |
| WO-1992004371-A1 | KININOGENASE INHIBITORS | FERRING PEPTIDE RESEARCH PARTNERSHIP KB (SE) | 1992-03-19 | — | — | WO | claimed |
| WO-1992002543-A1 | NOVEL IMMUNOSUPPRESSANT PEPTIDES | CYTEL CORPORATION (US) | 1992-02-20 | — | — | WO | claimed |
| EP-4731266-A1 | NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES | The Regents of the University of Michigan (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250325644-A1 | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | ELICIO THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-0262318-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1988-04-06 | — | — | EP | disclosed |
| US-4721776-A | Amino acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-01-26 | — | — | US | disclosed |
| EP-0222283-A2 | Amino-acid derivatives | MERCK PATENT GmbH (DE) | 1987-05-20 | — | — | EP | disclosed |
| EP-0220665-A2 | Peptides | MERCK PATENT GmbH (DE) | 1987-05-06 | — | — | EP | disclosed |
| EP-0118223-A1 | Enzyme inhibitors | Aktiebolaget Hässle (SE) | 1984-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | SMN1; SMN2 1799/4885EPHX2 4481/4885EPHX1 4621/4885 |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | ALB, FCGR3B, FCGR1A | SMN1; SMN2 2235/4885EPHX2 3020/4885EPHX1 2981/4885 |
| US-20030022821-A1 | Bioactive peptides | VIP, LITAF, LNPEP | SMN1; SMN2 3706/4885EPHX2 4683/4885EPHX1 4742/4885 |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | SMN1; SMN2 2679/4885EPHX2 316/4885EPHX1 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.